bevacizumab biosuperior (Xencor)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namebevacizumab biosuperior (Xencor)

Drug Alias Nameanti-VEGF human mAbs (Xencor)anti-VEGF human monoclonal antibodies (Xencor)Xtend-bevacizumabbevacizumab analogs (Xencor)Xtend-VEGF +[7]

ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionVascular endothelial growth factor inhibitors

TargetsVascular endothelial growth factor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXencor Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A